Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban

Journal of Thrombosis and Haemostasis

Volumn 10, Issue 7, 2012, Pages 1433-1436

  Harenberg, J ^a   Marx, S ^a   Weiss, C ^a   Kramer R ^a   Samama, M ^b   Schulman, S ^c  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b Biomnis Laboratory RetD   (France)

^c HENDERSON RESEARCH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

RIVAROXABAN;

ANTICOAGULATION; ARTICLE; BLOOD CLOTTING TEST; BLOOD SAMPLING; CLINICAL ARTICLE; DRUG BLOOD LEVEL; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTHROMBIN TIME;

ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CALIBRATION; CHROMOGENIC COMPOUNDS; DRUG MONITORING; FACTOR XA; HUMANS; MORPHOLINES; OBSERVER VARIATION; PREDICTIVE VALUE OF TESTS; PROTHROMBIN TIME; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; THIOPHENES;

EID: 84862146631     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2012.04784.x     Document Type: Article

References (21)

1. Eriksson BI, Kakkar AK, Turpie AG, Gent M, Bandel TJ, Homering M, Misselwitz F, Lassen MR. Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement. J Bone Joint Surg Br 2009; 91: 636-44.
2. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-91.
3. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-510.
4. Mismetti P, Laporte S. New oral antithrombotics: a need for laboratory monitoring. J Thromb Haemost 2010; 8: 621-6.
5. Rohde G. Determination of rivaroxaban - a novel, oral, direct factor Xa inhibitor - in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 872: 43-50.
6. Gerotziafas GT, Elalamy I, Depasse F, Perzborn E, Samama MM. In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban. J Thromb Haemost 2007; 5: 886-8.
7. Harder S, Parisius J, Picard-Willems B. Monitoring direct FXa-inhibitors and fondaparinux by Prothrombinase-induced Clotting Time (PiCT): relation to FXa-activity and influence of assay modifications. Thromb Res 2008; 123: 396-403.
8. Samama MM, Martinoli JL, LeFlem L, Guinet C, Plu-Bureau G, Depasse F, Perzborn E. Assessment of laboratory assays to measure rivaroxaban - an oral, direct factor Xa inhibitor. Thromb Haemost 2010; 103: 815-25.
9. Tripodi A, Chantarangkul V, Guinet C, Samama MM. The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study. J Thromb Haemost 2011; 9: 226-8.
10. Hillarp A, Baghaei F, Fagerberg Blixter I, Gustafsson KM, Stigendal L, Sten-Linder M, Strandberg K, Lindahl TL. Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays. J Thromb Haemost 2011; 9: 133-9.
11. Freyburger G, Macouillard G, Labrouche S, Sztark F. Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement. Thromb Res 2011; 127: 457-65.
12. Mani H, Hesse C, Stratmann G, Lindhoff-Last E. Rivaroxaban differentially influences ex vivo global coagulation assays based on the administration time. Thromb Haemost 2011; 106: 156-64.
13. Harenberg J, Marx S, Kramer R, Giese C, Weiss C. Determination of an international sensitivity index of thromboplastin reagents using a WHO thromboplastin as calibrator for plasma spiked with rivaroxaban. Blood Coagul Fibrinolysis 2011; 22: 637-41.
14. Gerotziafas GT, Baccouche H, Sassi M, Galea V, Chaari M, Hatmi M, Samama MM, Elalamy I. Optimisation of the assays for the measurement of clotting factor activity in the presence of rivaroxaban. Thromb Res 2011; 129: 101-3.
15. Roehrig S, Straub A, Pohlmann J, Lampe T, Pernerstorfer J, Schlemmer KH, Reinemer P, Perzborn E. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1, 3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J Med Chem 2005; 48: 5900-8.
16. Maloney CJ. Significance tests for Grubb's estimators. Biometrics 1970; 26: 671-5.
17. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005; 78: 412-21.
18. Krummenauer F. Intraindividual scale comparison in clinical diagnostic methods: a review of elementary methods. Biom J 1999; 41: 917-29.
19. Barrowcliffe TW, Curtis AD, Johnson EA, Thomas DP. An international standard for low molecular weight heparin. Thromb Haemost 1988; 60: 1-7.
20. Gray E, Walker AD, Mulloy B, Barrowcliffe TW. A collaborative study to establish the 5th International Standard for Unfractionated Heparin. Thromb Haemost 2000; 84: 1017-22.
21. Gray E, Harenberg J. Collaborative study on monitoring methods to determine direct thrombin inhibitors lepirudin and argatroban. J Thromb Haemost 2005; 3: 2096-7.